// App-Quantinova.ai

FRI0575 : BIOMARKER ANALYSIS FROM THE RISE-SSC STUDY OF RIOCIGUAT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)

Researchers

Presenter

  • O. Distler

Principal Investigators

  • J. Hfler

  • M. Ghadessi

  • P. Sandner

  • Y. Allanore

  • C. Denton

  • M. Kuwana

  • M. Matucci-Cerinic

  • J. Pope

  • T. Atsumi

  • R. Becvr

  • L. Czirjk

  • E. De Langhe

  • E. Hachlla

  • T. Ishii

  • O. Ishikawa

  • S. Johnson

  • K. Laapas

  • V. Riccieri

  • E. Schiopu

  • R. Silver

  • V. Smith

  • C. Stagnaro

  • V. Steen

  • W. Stevens

  • G. Szcs

  • M. E. Truchetet

  • M. Wosnitza

  • D. Khanna

Medical Centers

  • Univ Hosp, Zurich, Switzerland

  • Bayer Pharma AG, Berlin, Germany

  • Staburo GmbH, Munich, Germany

  • Paris Descartes University, Paris, France

  • NCRI, London, United Kingdom

  • Nippon Medical School, Tokyo, Japan

  • University of Florence, Florence, Italy

  • The Univ of Western Ontario, London, Canada

  • Hokkaido Univ., Sapporo, Japan.

  • Charles Univ and VFN, Prague, Czech Republic

  • Univ Pécs Medical School, Pécs, Hungary

  • Univ Hosps Leuven, Leuven, Belgium

  • Tohuko Univ, Sendai, Japan

  • Gunma University Hospital, Maebashi, Japan

  • UHN, Toronto, Ontario, Canada.

  • StatFinn Oy, Espoo, Finland,

  • University la Sapienza, Rome, Italy

  • Michigan Medicine Univ Hosp, Ann Arbor, Michigan, United States of America

  • Medical University of South Carolina, Charleston, United States of America

  • Ghent University Hospital, Ghent, Belgium

  • Univ. of Pisa, Pisa, Italy

  • Georgetown Univ, Washington, United States of America

  • St Vincent's Hospital, Melbourne, Australia

  • Univ Debrecen, Egyetem, Hungary

  • Bordeaux University, Bordeaux, France

  • U Michigan, Ann Arbor, Michigan, United States

Locations

  • Switzerland

  • Germany

  • France

  • United Kingdom

  • Japan

  • Italy

  • Canada

  • Czech Republic

  • Hungary

  • Belgium

  • Finland

  • United States

  • Australia

Companies

  • Staburo GmbH

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Scleroderma

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • E-selectin

  • High sensitivity C-reactive protein

Drug/Treatment

  • Riociguat

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • NCT02283762

Sponsors

  • Bayer AG and Merck Sharp & Dohme Corp(MSD)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved